Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (3321)	8/27/1999 1:44:00 AM
From: BDR	Respond to of 10293

Re HRC (a few months old but pertinent): << June 15, 1999/FOOLWIRE/ -- "Separating our inpatient and outpatient businesses will allow us to provide better service to our patients and payors," said Richard Scrushy, chairman and CEO of outpatient surgery and rehabilitative services provider HEALTHSOUTH Corp. (NYSE: HRC), in a statement today. HEALTHSOUTH's stock rose $1 3/8 to $15 9/16 today on news of plans to split the company's inpatient and outpatient operations into two publicly traded companies. Of course, the company extolled the virtues of its integrated service model in its April annual report, but that's all ancient medical history now. Acquisitive HEALTHSOUTH, its shares currently fetching about half their Summer '97 prices, hopes to stir up investor confidence in its outpatient business, which boasts higher profitability, more acquisition-fueled growth potential, and less reliance on government payors than the inpatient division. In 1998, same-store inpatient days rose about 33%, compared with outpatient visit growth of 28%, but revenue per inpatient day fell nearly 6% for the year compared with essentially flat revenue for each outpatient visit, exacerbating a trend also evident in 1997. >> If they are going to spin off the outpatient unit (in which case the inpatient unit would go terminal) how does this help? If revenue is flat (and no one is going to pay providers/hospitals more in the future) how much more can you squeeze out of the system on either side? Anyone see other healthcare shorts?

To: BDR who wrote (3321)	8/27/1999 1:51:00 AM
From: BDR	Read Replies (1) \| Respond to of 10293

Let the number counting begin: Hextend Sales Begin, BioTime Receives Milestone Payments August 26, 1999 BERKELEY, Calif.--(BW HealthWire) via NewsEdge Corporation -- BioTime, Inc. (NASDAQ:BTIM) today announced that it has received milestone payments due from Abbott Laboratories under its Exclusive License Agreement for Hextend(R), BioTime's proprietary physiologically balanced blood plasma volume expander. BioTime received a total of $850,000 from Abbott for achieving FDA approval of Hextend(R) and commencing sales under the agreement. "Hextend(R) is now available to hospitals and clinics across the United States," said Dr. Paul Segall, BioTime chairman and chief executive officer. "With Abbott directing the marketing effort of this exciting new product, we look forward to increasing awareness and acceptance by physicians. " Hextend(R) was approved for the treatment of large volume blood loss during surgery, and is the only plasma expander that contains multiple electrolytes, glucose, a physiological buffer and hetastarch. Hextend(R) is also completely sterilized to avoid risk of infection. Hextend(R) addresses a domestic market for surgical solutions thought to exceed $400 million in size annually. The largest segment of this market is currently albumin sales. In BioTime's Phase III clinical trials which led to Hextend(R)'s approval, albumin which is derived from human blood, was not used intraoperatively. The Phase III clinical trial investigators reported that an average of 1.6 liters of Hextend(R) was used in surgical procedures. No serious related adverse events were reported, even when Hextend(R) was given in volumes as high as 2 to 5 liters. BioTime, headquartered in Berkeley, California, is engaged in the research and development of blood plasma volume expanders, solutions for low temperature surgery and organ preservation, and technology for use in surgery, emergency trauma treatment, the preservation of organs awaiting transplant, and other applications. The matters discussed in this press release include forward-looking statements ...etc. CONTACT: BioTime, Inc. \| Ronald Barkin, 510/845-9535 [Copyright 1999, Business Wire]

To: BDR who wrote (3321)	8/27/1999 1:57:00 AM
From: BDR	Read Replies (1) \| Respond to of 10293

Did Bill make a call on this one? Directors run like hell. Sabratek Announces Resignations of Two Directors August 26, 1999 SKOKIE, Ill., Aug. 25 /PRNewswire/ via NewsEdge Corporation -- The Board of Directors of Sabratek Corporation (Nasdaq: SBTKE) today announced that L. Peter Smith, Chairman and Chief Executive Officer of Ralin Medical, Inc., and Mark Lampert, Managing Partner, Biotechnology Value Fund, L.P., have resigned from the Sabratek Board, effective immediately. Mr. Smith joined the Board in October 1992, and Mr. Lampert joined in May 1996. The Board said that both Mr. Smith and Mr. Lampert cited the need to devote their full business attention to other endeavors as the reason for their decisions to leave. The Board also said that although it was sorry to see these Directors leave, it will keep its number of Board members at seven instead of nine in order to streamline its decision-making process and to accelerate efforts to enhance shareholder value. The Board gratefully acknowledges the contribution that these two gentlemen made to the Company. Based in Skokie, Illinois, Sabratek Corporation is a clinical connectivity company. The Company develops, produces and markets technologically advanced, easy-to-use, smart, interactive, Web-enabled medical systems that work seamlessly together to allow health-care providers to lower costs, expand access and maintain quality across the continuum of care. This press release contains forward-looking statements. The actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements are contained in the Company's periodic reports filed under the Securities Exchange Act of 1934, as amended (copies of which are available upon request from the Company's Investor Relations Department). SOURCE Sabratek Corporation /CONTACT: John Reilly, Chief Financial Officer of Sabratek Corporation, 847-720-2400; or Investor Relations - Mark Kollar or Jeffrey Rendin of Broadgate Consultants, Inc., 212-232-2222/ (SBTKE) [Copyright 1999, PR Newswire]